BioCentury
ARTICLE | Company News

Takeda Pharmaceuticals Co. Ltd. sales and marketing update

February 2, 2015 8:00 AM UTC

Takeda launched IV fomepizole in Japan to treat ethylene glycol and methanol poisoning. Takeda has exclusive, Japanese rights to develop and commercialize the product under a May 2011 deal with Paladin Labs Inc., which Endo International plc (NASDAQ:ENDP; TSX:ENL, Dublin, Ireland) subsequently acquired (see BioCentury, May 16, 2011). ...